Apricus gets milestone payment for Vitaros commercialisation deal
Apricus Biosciences has received a US$2.5 million payment from Abbott under its commercial partnership with the company for Vitaros (topical alprostadil) for erectile dysfunction (ED) in Canada. Also, Apricus successfully produced six consecutive commercial-size validation batches of Vitaros in 220 and 330mcg forms. Apricus granted Abbott exclusive rights to market Vitaros in Canada in January 2012.
Vitaros is applied topically, which helps to reduce side effects and offers men who do not do well with the existing oral drugs a patient-friendly alternative. When absorbed through the skin, Vitaros directly boosts blood flow, thereby causing an erection within minutes - faster than the results achieved from the oral medications. Vitaros combines alprostadil with Apricus' NexACT delivery technology, which allows the drug to pass through the skin.